$TSHA
Taysha Gene Therapies, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$4.49
▲+1.35%+$0.060
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateTaysha Gene Therapies, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is TSHA up today? It is at $4.49 (+1.35%), and our scanner flagged it 74 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment TSHA spikes, and full due diligence on TSHA — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $TSHA 74 times in the last 30 days. Create a free account to track $TSHA, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on TSHA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for TSHA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystTaysha Gene Therapies, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filingSC 13G/APassive 5%+ stake updatedAug 14, 2026 · 56 days agoThe company can keep selling new shares into the market. Size not stated in the filing.
Some filings did not state a size, so these are floors.
At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing)
33,333,334 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · About $187.4M in size · Priced at $6/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Nagendran Sukumar Officer | Sold (automatic/other) | -200K 0.06% of company | sold 18% | 936K | $1.2M at $6.24 | Jul 10, 26 |
Donenberg Phillip B. Director | Acquired (grant/award) | +21K | added 9.7% | 241K | n/a | Jun 1, 26 |
Long Alison S Director | Acquired (grant/award) | +21K | added 20% | 127K | n/a | Jun 1, 26 |
Sepp-Lorenzino Laura Director | Acquired (grant/award) | +21K | added 20% | 127K | n/a | Jun 1, 26 |
Stalfort John A Iii Director | Acquired (grant/award) | +21K | added 1.8% | 1.18M | n/a | Jun 1, 26 |
Nagendran Sukumar Officer | Sold (automatic/other) | -200K 0.06% of company | sold 15% | 1.14M | $892K at $4.46 | Apr 10, 26 |
Nagendran Sukumar Officer | Other | 19K | added 1.4% | 1.34M | $33K at $1.71 | Apr 10, 26 |
Alam Kamran Officer | Sold (automatic/other) | -2K | sold 0.1% | 1.44M | $7K at $4.52 | Feb 4, 26 |
Alam Kamran Officer | Sold (automatic/other) | -24K | sold 1.6% | 1.44M | $110K at $4.61 | Jan 26, 26 |
Nolan Sean P. Officer | Sold (automatic/other) | -41K 0.01% of company | sold 1.4% | 2.91M | $190K at $4.61 | Jan 26, 26 |
Nagendran Sukumar Officer | Sold (automatic/other) | -27K | sold 2.0% | 1.32M | $124K at $4.61 | Jan 26, 26 |
Alam Kamran Officer | Sold (automatic/other) | -79K 0.02% of company | sold 5.1% | 1.47M | $375K at $4.75 | Jan 23, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on TSHA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for TSHA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
TSHA last traded at $4.49, up 1.35% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Taysha Gene Therapies, Inc. Common Stock (TSHA) is next expected to report earnings on Tuesday, November 3, 2026, about 24 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The TSHA Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged TSHA 74 times in the last 30 days.
TSHA (Taysha Gene Therapies, Inc. Common Stock) trades on XNAS, with a market cap of about $1.46B in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge TSHA for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$TSHA discussion
Sign in to ask a question or join the discussion.